Abstract
The INK4a/ARF locus at chromosome 9p21 encodes two structurally and functionally distinct molecules with tumor-suppressive properties. p16INK4a controls cell cycle progression by inhibiting phosphorylation of the retinoblastoma protein (Rb), while ARF prevents MDM2-mediated degradation of p53. By using a panel of PCR-based methods, we have examined the status of the p16INK4a, ARF and p53 genes in 123 cases of non-Hodgkin's lymphoma (NHL) at diagnosis. Alterations of one or more of these genes were detected in seven of 36 (19%) cases with low- to intermediate-grade histology, and in 35 of 87 (40%) cases with aggressive histology. For the aggressive lymphomas, the Kaplan–Meier estimate of overall survival for cases with disruption of either p16INK4a or the ARF-p53 pathway was not different from cases with retention of both pathways (5-year survival 45% vs 35%; P = 0.85), suggesting that selective inactivation of one of the pathways does not significantly influence overall survival. By contrast, the 5-year survival was only 7% for cases with concurrent disruption of p16INK4a and the ARF-p53 pathway vs 38% for cases with retention of one or both pathways (P = 0.005). Similar results were obtained when the analysis was confined to diffuse large B cell lymphomas (P = 0.019). On stepwise multivariate regression analysis including factors from the international prognostic index, concurrent disruption of p16INK4a and the ARF-p53 pathway was an independent negative prognostic factor in NHL with aggressive histology (P = 0.006). Our results suggest that the compound status of the p16INK4a and ARF-p53 pathways is a major determinant of outcome in NHL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA . A revised European–American classification of lymphoid neoplasms: a proposal from the international lymphoma study group Blood 1994 84: 1361–1392
The International Non-Hodgkin's Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin's lymphoma New Engl J Med 1993 329: 987–994
Howard OM, Shipp MA . The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas Curr Opin Oncol 1998 10: 385–391
Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R . p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia Proc Natl Acad Sci USA 1991 88: 5413–5417
Villuendas R, Sanchez-Beato M, Martinez JC, Saez AI, Martinez-Delgado B, Garcia JF, Mateo MS, Sanchez-Verde L, Benitez J, Martinez P, Piris MA . Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression Am J Pathol 1998 153: 887–897
Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MA, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E . Deletions and rearrangement of CDKN2 in lymphoid malignancy Blood 1995 85: 893–901
Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez PL, Montserrat E, Cardesa A, Campo E . p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas Blood 1998 91: 2977–2984
Herman JG, Civin CI, Issa J-PJ, Collector MI, Sharkis SJ, Baylin SB . Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies Cancer Res 1997 57: 837–841
Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M . Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas Blood 1997 89: 601–609
Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T . Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma New Engl J Med 1997 337: 529–534
Koduru PR, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD . Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma Blood 1995 86: 2900–2905
Møller MB, Ino Y, Gerdes AM, Skjødt K, Louis DN, Pedersen NT . Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma Leukemia 1999 13: 453–459
Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR, Weisenburger DD . p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis Blood 1996 87: 4302–4310
Pinyol M, Hernandez L, Cazorla M, Balbin M, Jares P, Fernandez PL, Montserrat E, Cardesa A, Lopez Otin C, Campo E . Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas Blood 1997 89: 272–280
Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M, Kolitz J, Broome JD . Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma Blood 1997 90: 4078–4091
Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG . p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma Blood 1998 91: 1680–1687
Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M . p53 mutation is associated with progression in follicular lymphomas Blood 1993 82: 1994–2004
Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M . Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma Blood 1998 91: 4677–4685
Gombart AF, Morosetti R, Miller CW, Said JW, Koeffler HP . Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas Blood 1995 86: 1534–1539
Otsuki T, Clark HM, Wellmann A, Jaffe ES, Raffeld M . Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas Cancer Res 1995 55: 1436–1440
Garcia-Sanz R, Gonzalez M, Vargas M, Chillon MC, Balanzategui A, Barbon M, Flores MT, San Miguel JF . Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas Leukemia 1997 11: 1915–1920
Uchida T, Watanabe T, Kinoshita T, Murate T, Saito H, Hotta T . Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas Blood 1995 86: 2724–2731
Levine AJ . p53, the cellular gatekeeper for growth and division Cell 1997 88: 323–331
Sherr CJ . Cancer cell cycles Science 1996 274: 1672–1677
Serrano M, Hannon GJ, Beach D . A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature 1993 366: 704–707
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D . p21 is a universal inhibitor of cyclin kinases Nature 1993 366: 701–704
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B . WAF1, a potential mediator of p53 tumor suppression Cell 1993 75: 817–825
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ . The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases Cell 1993 75: 805–816
Sherr CJ . Tumor surveillance via the ARF-p53 pathway Genes Dev 1998 12: 2984–2991
Prives C . Signaling to p53: breaking the MDM2-p53 circuit Cell 1998 95: 5–8
de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW . E1A signaling to p53 involves the p19(ARF) tumor suppressor Genes Dev 1998 12: 2434–2442
Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF . Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization Genes Dev 1998 12: 2424–2433
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ . Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF Cell 1997 91: 649–659
Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G . The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2 EMBO J 1998 17: 5001–5014
Quelle DE, Zindy F, Ashmun RA, Sherr CJ . Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest Cell 1995 83: 993–1000
Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A . Complex structure and regulation of the p16 (MTS1) locus Cancer Res 1995 55: 2988–2994
Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D . A novel p16INK4A transcript Cancer Res 1995 55: 2995–2997
Duro D, Bernard O, Della VV, Berger R, Larsen CJ . A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies Oncogene 1995 11: 21–29
Zhang Y, Xiong Y, Yarbrough WG . ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways Cell 1998 92: 725–734
Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA . The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 1998 92: 713–723
Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ . Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 Proc Natl Acad Sci USA 1998 95: 8292–8297
Zhang Y, Xiong Y . Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53 Mol Cell 1999 3: 579–591
Tao W, Levine AJ . P19ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2 Proc Natl Acad Sci USA 1999 96: 6937–6941
Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D . Nucleolar Arf sequesters Mdm2 and activates p53 Nat Cell Biol 1999 1: 20–26
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CAJ, Butel JS, Bradley A . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours Nature 1992 356: 215–221
Kumar R, Sauroja I, Punnonen K, Jansen C, Hemminki K . Selective deletion of exon 1β of the p19ARF gene in metastatic melanoma cell lines Genes Chromosomes Cancer 1998 23: 273–277
Gardie B, Cayuela JM, Martini S, Sigaux F . Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia Blood 1998 91: 1016–1020
Gonzalgo ML, Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT, Jones PA . The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines Cancer Res 1998 58: 1245–1252
Robertson KD, Jones PA . The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53 Mol Cell Biol 1998 18: 6457–6473
Markl ID, Jones PA . Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer Cancer Res 1998 58: 5348–5353
Brenner AJ, Paladugu A, Wang H, Olopade OI, Dreyling MH, Aldaz CM . Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer Clin Cancer Res 1996 2: 1993–1998
Baur AS, Shaw P, Burri N, Delacretaz F, Bosman FT, Chaubert P . Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas Blood 1999 94: 1773–1781
Grønbæk K, Nedergaard T, Andersen MK, thor Straten P, Guldberg P, Møller P, Zeuthen J, Hansen NE, Hou-Jensen K, Ralfkiaer E . Concurrent disruption of cell cycle associated genes in mantle cell lymphoma. A genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb Leukemia 1998 12: 1266–1271
Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN . CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated Cancer Res 1996 56: 150–153
Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH, Tucker MA, Dracopoli NC . Germline p16 mutations in familial melanoma Nat Genet 1994 8: 15–21
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D . 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers Nature Med 1995 1: 686–692
Herman JG, Jen J, Merlo A, Baylin SB . Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B1 Cancer Res 1996 56: 722–727
Guldberg P, Grønbæk K, Aggerholm A, Platz A, thor Straten P, Ahrenkiel V, Hokland P, Zeuthen J . Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis Nucleic Acids Res 1998 26: 1548–1549
Wang RY, Gehrke CW, Ehrlich M . Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues Nucleic Acids Res 1980 8: 4777–4790
Zeschnigk M, Lich C, Buiting K, Doerfler W, Horsthemke B . A single-tube PCR test for the diagnosis of Angelman and Prader–Willi syndrome based on allelic methylation differences at the SNRPN locus Eur J Hum Genet 1997 5: 94–98
Abrams ES, Stanton VP . Use of denaturing gradient gel electrophoresis to study conformational transitions in nucleic acids Meth Enzymol 1992 212: 71–104
Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J . Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer Hum Mutat 1997 9: 348–355
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Cox DR . Regression models and life tables J Roy Stat Soc 1972 34: 187–220
Aggerholm A, Guldberg P, Hokland M, Hokland P . Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia Cancer Res 1999 59: 436–441
Greenblatt MS, Bennett WP, Hollstein M, Harris CC . Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res 1994 54: 4855–4878
Cho Y, Gorina S, Jeffrey PD, Pavletich NP . Crystal structure of a p53 tumor suppressor–DNA complex: understanding tumorigenic mutations Science 1994 265: 346–355
Della Valle V, Duro D, Bernard O, Larsen CJ . The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alternative β transcript of the p16INK4a/MTS1 gene Oncogene 1997 15: 2475–2481
Gazzeri S, Della VV, Chaussade L, Brambilla C, Larsen CJ, Brambilla E . The human p19ARF protein encoded by the β transcript of the p16INK4a gene is frequently lost in small cell lung cancer Cancer Res 1998 58: 3926–3931
Zhuang SM, Schippert A, Haugen-Strano A, Wiseman RW, Soderkvist P . Inactivations of p16INK4a-α, p16INK4a-β and p15INK4b genes in 2′,3′-dideoxycytidine- and 1,3-butadiene-induced murine lymphomas Oncogene 1998 16: 803–808
Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C . Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence Am J Pathol 1999 155: 105–113
Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T . Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos Mol Cell 1998 2: 293–304
Pan H, Yin C, Dyson NJ, Harlow E, Yamasaki L, Dyke TV . Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors Mol Cell 1998 2: 283–292
Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH . p14ARF links the tumour suppressors RB and p53 Nature 1998 395: 124–125
Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Muller-Hermelink HK, Bentz M, Hiddemann W, Dohner H . Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma Cancer Res 1997 57: 4608–4614
Dreyling MH, Bohlander SK, Le Beau MM, Olopade OI . Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies Blood 1995 86: 1931–1938
Acknowledgements
This study was supported by grants from the Danish Cancer Society, the E Danielsen Foundation, the Kaarsen Foundation, the Danish Medical Research Council, the Danish Cancer Research Foundation, and the Novo Nordisk Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grønbæk, K., de Nully Brown, P., Møller, M. et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 14, 1727–1735 (2000). https://doi.org/10.1038/sj.leu.2401901
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401901
Keywords
This article is cited by
-
Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma
Leukemia (2007)
-
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH
Oncogene (2007)
-
Gene arrays in lymphoma: Where will they fit in?
Current Hematologic Malignancy Reports (2006)
-
High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model
Breast Cancer Research and Treatment (2006)
-
Promoter hypermethylation and protein expression of the p16 gene: analysis of 43 cases of B-cell primary gastric lymphomas from China
Modern Pathology (2004)